<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33065281</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.</ArticleTitle><Pagination><StartPage>105130</StartPage><MedlinePgn>105130</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2020.105130</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(20)30405-8</ELocationID><Abstract><AbstractText>Proteinaceous aggregates are major hallmarks of several neurodegenerative diseases. Aggregates of post-translationally modified transactive response (TAR)-DNA binding protein 43 (TDP-43) in cytoplasmic inclusion bodies are characteristic features in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Recent studies have also reported TDP-43 aggregation in Alzheimer's disease (AD). TDP-43 is an RNA/DNA binding protein (RBP) mainly present in the nucleus. In addition to several RBPs, TDP-43 has also been reported in stress granules in FTD and ALS pathologies. Despite knowledge of cytoplasmic mislocalization of TDP-43, the cellular effects of TDP-43 aggregates and their cytotoxic mechanism(s) remain to be clarified. We hypothesize that TDP-43 forms oligomeric assemblies that associate with tau, another key protein involved in ALS and FTD. However, no prior studies have investigated the interactions between TDP-43 oligomers and tau. It is therefore important to thoroughly investigate the cross-seeding properties and cellular localization of both TDP-43 and tau oligomers in neurodegenerative diseases. Here, we demonstrate the effect of tau on the cellular localization of TDP-43 in WT and P301L tau-inducible cell models (iHEK) and in WT HEK-293 cells treated exogenously with soluble human recombinant tau oligomers (Exo-rTauO). We observed cytoplasmic TDP-43 accumulation o in the presence of tau in these cell models. We also studied the occurrence of TDP-43 oligomers in AD, ALS, and FTD human brain tissue using novel antibodies generated against TDP-43 oligomers as well as generic TDP-43 antibodies. Finally, we examined the cross-seeding property of AD, ALS, and FTD brain-derived TDP-43 oligomers (BDT43Os) on tau aggregation using biochemical and biophysical assays. Our results allow us to speculate that TDP-43/tau interactions might play a role in AD, ALS, and FTD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montalbano</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAllen</LastName><ForeName>Salome</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cascio</LastName><ForeName>Filippa Lo</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sengupta</LastName><ForeName>Urmi</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatt</LastName><ForeName>Nemil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellsworth</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidelman</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Texas Medical Branch, UTMB, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Omar D</ForeName><Initials>OD</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Texas Medical Branch, UTMB, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doskocil</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience Summer Undergraduate Research Program, NSURP Program 2018, University of Texas Medical Branch, UTMB, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: rakayed@utmb.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG055771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054025</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG060718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094557</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="N">Pick Disease of the Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggregation</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Oligomer</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">Tauopathies</Keyword></KeywordList><CoiStatement>Conflict of Interest: None. Declaration of Interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>16</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33065281</ArticleId><ArticleId IdType="mid">NIHMS1642231</ArticleId><ArticleId IdType="pmc">PMC7703712</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2020.105130</ArticleId><ArticleId IdType="pii">S0969-9961(20)30405-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afroz T, et al., 2017. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nature Communications. 8, 45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK, 2019. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Frontiers in Neuroscience. 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittar A, et al., 2019. Neurotoxic tau oligomers after single versus repetitive mild traumatic brain injury. Brain communications. 1, fcz004&#x2013;fcz004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777515</ArticleId><ArticleId IdType="pubmed">31608324</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA, 2019. RNA Dysregulation in Amyotrophic Lateral Sclerosis. Frontiers in Genetics. 9.</Citation></Reference><Reference><Citation>Castillo-Carranza DL, et al., 2018. &#x3b1;-Synuclein Oligomers Induce a Unique Toxic Tau Strain. Biol Psychiatry. 84, 499&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201292</ArticleId><ArticleId IdType="pubmed">29478699</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang XL, et al., 2016. The Role of TDP-43 in Alzheimer&#x2019;s Disease. Mol Neurobiol. 53, 3349&#x2013;3359.</Citation><ArticleIdList><ArticleId IdType="pubmed">26081142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cohen TJ, 2019. Aggregation of the nucleic acid-binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J Biol Chem. 294, 3696&#x2013;3706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416430</ArticleId><ArticleId IdType="pubmed">30630951</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirita CN, et al., 2003. Anionic micelles and vesicles induce tau fibrillization in vitro. J Biol Chem. 278, 25644&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730214</ArticleId></ArticleIdList></Reference><Reference><Citation>Choksi DK, et al., 2014. TDP-43 Phosphorylation by casein kinase Iepsilon promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet. 23, 1025&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">24105464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y, et al., 2019. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Lab Invest. 99, 993&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609463</ArticleId><ArticleId IdType="pubmed">30742063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C-C, et al., 2018. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nature Neuroscience. 21, 228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremers CM, et al., 2016. Polyphosphate: A Conserved Modifier of Amyloidogenic Processes. Mol Cell. 63, 768&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234082</ArticleId><ArticleId IdType="pubmed">27570072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Dormann D, 2017. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett. 591, 1489&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pubmed">28380257</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaum-Garfinkle S, 2019. Matter over mind: Liquid phase separation and neurodegeneration. J Biol Chem. 294, 7160&#x2013;7168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509495</ArticleId><ArticleId IdType="pubmed">30914480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, et al., 2011. FTD and ALS: a tale of two diseases. Curr Alzheimer Res. 8, 273&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801195</ArticleId><ArticleId IdType="pubmed">21222600</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, et al., 2018. Pathomechanisms of TDP-43 in neurodegeneration. Journal of neurochemistry. 10.1111/jnc.14327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId><ArticleId IdType="pmc">PMC6110993</ArticleId><ArticleId IdType="pubmed">29486049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, et al., 2019. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron. 102, 339&#x2013;357 e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson JE, et al., 2017. Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. Methods Mol Biol. 1523, 141&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">27975249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson JE, et al., 2014. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta neuropathologica communications. 2, 73&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229782</ArticleId><ArticleId IdType="pubmed">24927818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghag G, et al., 2018. Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. Protein Sci. 27, 1901&#x2013;1909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201727</ArticleId><ArticleId IdType="pubmed">30125425</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, et al., 2017. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies. The Journal of biological chemistry. 292, 10600&#x2013;10612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5481566</ArticleId><ArticleId IdType="pubmed">28487370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, et al., 2019. Cyclic AMP-Dependent Protein Kinase Phosphorylates TDP-43 and Modulates Its Function in Tau mRNA Processing. Journal of Alzheimer&#x2019;s disease : JAD. 70, 1093&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">31306131</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL, et al., 2018. Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat Struct Mol Biol. 25, 463&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero-Mu&#xf1;oz MJ, et al., 2014. Amyloid-&#x3b2; oligomers as a template for secondary amyloidosis in Alzheimer&#x2019;s disease. Neurobiol Dis. 71, 14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25134727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedl TJ, et al., 2019. Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD. Frontiers in Neuroscience. 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579929</ArticleId><ArticleId IdType="pubmed">31244593</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, et al., 2007. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 1184, 284&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, et al., 2009. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 284, 20329&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al., 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300, 486&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, et al., 2012. Identification of oligomers at early stages of tau aggregation in Alzheimer&#x2019;s disease. FASEB J. 26, 1946&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, et al., 2013. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 79, 416&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Cascio F, et al., 2020. Modulating Disease-Relevant Tau Oligomeric Strains by Small Molecules. J Biol Chem.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606668</ArticleId><ArticleId IdType="pubmed">32737202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Cascio F, Kayed R, 2018a. Azure C Targets and Modulates Toxic Tau Oligomers. ACS Chem Neurosci. 9, 1317&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">29378132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Cascio F, Kayed R, 2018b. Azure C Targets and Modulates Toxic Tau Oligomers. 9, 1317&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">29378132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Cascio F, et al., 2019. Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. Sci Rep. 9, 19011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6908736</ArticleId><ArticleId IdType="pubmed">31831807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, et al., 2020. ALS and FTD: Where RNA metabolism meets protein quality control. Semin Cell Dev Biol. 99, 183&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">31254610</ArticleId></ArticleIdList></Reference><Reference><Citation>Margittai M, Langen R, 2004. Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci U S A. 101, 10278&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC478563</ArticleId><ArticleId IdType="pubmed">15240881</ArticleId></ArticleIdList></Reference><Reference><Citation>Margittai M, Langen R, 2006. Side chain-dependent stacking modulates tau filament structure. J Biol Chem. 281, 37820&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023423</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, et al., 2017. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol. 27, 472&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Monahan Z, et al., 2016. Stress granules at the intersection of autophagy and ALS. Brain Res. 1649, 189&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055418</ArticleId><ArticleId IdType="pubmed">27181519</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbano M, et al., 2020a. RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction. Nat Commun. 11, 4305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453003</ArticleId><ArticleId IdType="pubmed">32855391</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbano M, et al., 2020b. RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction. Nature Communications. 11, 4305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453003</ArticleId><ArticleId IdType="pubmed">32855391</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbano M, et al., 2019. Tau oligomers mediate aggregation of RNA-binding proteins Musashi1 and Musashi2 inducing Lamin alteration. Aging Cell. 18, e13035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6826126</ArticleId><ArticleId IdType="pubmed">31532069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutreja Y, Gamblin TC, 2017. Optimization of in vitro conditions to study the arachidonic acid induction of 4R isoforms of the microtubule-associated protein tau. Methods Cell Biol. 141, 65&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">28882312</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al., 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 314, 130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbacher JK, et al., 2015. RNA-binding proteins in neurodegeneration: Seq and you shall receive. Trends in neurosciences. 38, 226&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403644</ArticleId><ArticleId IdType="pubmed">25765321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbacher JK, et al., 2019. Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions. Neuron. 102, 294&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545120</ArticleId><ArticleId IdType="pubmed">30998900</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, et al., 2019. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience. 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Puangmalai N, et al., 2020. Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer&#x2019;s disease, progressive supranuclear palsy and dementia with Lewy bodies. Cell Death Dis. 11, 314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198578</ArticleId><ArticleId IdType="pubmed">32366836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Buratti E, 2016. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J Neurochem. 138 Suppl 1, 95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta U, et al., 2018a. Preparation and Characterization of Tau Oligomer Strains. Methods in molecular biology (Clifton, N.J.). 1779, 113&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">29886531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta U, et al., 2018b. Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer&#x2019;s disease. Acta Neuropathologica Communications. 6, 113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6203984</ArticleId><ArticleId IdType="pubmed">30367664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta U, et al., 2020. Polymorphic &#x3b1;-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. Molecular Neurobiology.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253398</ArticleId><ArticleId IdType="pubmed">32350746</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiina Y, et al., 2010. TDP-43 dimerizes in human cells in culture. Cell Mol Neurobiol. 30, 641&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">20043239</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T, 2018. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neuropathology. 38, 72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">28960544</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay C, et al., 2011. Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol. 70, 788&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197017</ArticleId><ArticleId IdType="pubmed">21865887</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>